Get started
Author

Alan Tan

ORCID: 0000-0002-6350-5917
Observed ORCID: 0000-0002-6350-5917
OpenAlex ID: A5124946737
Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026 · George Ansstas, Karam Khaddour, et al. · Clinical Cancer Research · 9
PDF
A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).
2026 · Rana R. McKay, Pamela J. Atherton, et al. · Journal of Clinical Oncology · 1
Use of ultra-sensitive whole genome circulating tumor DNA detection to predict early recurrence in high-risk localized RCC after nephrectomy: Preliminary real-world findings.
2026 · Paulo Siqueira do Amaral, Mehmet Murat Zerey, et al. · Journal of Clinical Oncology · 1
PDF
Final results of Alliance A031902: A phase III trial of enzalutamide plus rucaparib as first-line therapy in metastatic castration-resistant prostate cancer (CASPAR).
2026 · Charles J. Ryan, David W. Hillman, et al. · Journal of Clinical Oncology
Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102).
2026 · Yu-Wei Chen, Olivia Bobek, et al. · Journal of Clinical Oncology
Erratum: Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors
2026 · Rebecca Hassoun, Reuben Ben-David, et al. · JCO Precision Oncology
PDF
Whole genome–based ultrasensitive circulating tumor DNA clearance as a biomarker of exceptional outcomes with enfortumab vedotin and pembrolizumab in urothelial carcinoma: Preliminary real-world results.
2026 · Mehmet Murat Zerey, Paulo Siqueira do Amaral, et al. · Journal of Clinical Oncology
PDF
Works count: 7
Citation count: 11
H-index: 1
I10-index:
Year
Topic
Type